Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment increased: 60 → 105 participants
    • Eligibility criteria expanded, about 13 words
  2. Trial sites expanded: 23 → 32 locationsv9
  3. Trial sites expanded: 20 → 23 locationsv8
  4. Trial sites expanded: 17 → 20 locationsv7
  5. Enrollment target: 64 to 60
    • Eligibility criteria shortened, about 59 words
    • Secondary endpoints: 17 to 6
    • Study sites revised (17)
    v6
  6. Trial sites expanded: 12 → 17 locationsv5
  7. Study sites: 5 to 12v4
  8. Study sites: 1 to 5v3
  9. Site contact updatedv2
  10. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to learn about the safety and effectiveness of ENV-294 in adults with moderate to severe atopic dermatitis. The main questions it will answer are: * Is there an impact on the severity and area of atopic dermatitis when participants take ENV-294 * What medical problems do participants have when taking ENV-294 Participants will: * Take drug ENV-294 or a placebo once every day for 12 weeks * Visit the clinic every 2 to 4 weeks for checkups and tests * Keep a diary of their symptoms and when they took their study drug * Return to the clinic for the final study visit at approximately week 16
Trial Details
NCT Number NCT07298395
Lead Sponsor Enveda Therapeutics
Conditions
(from sponsor)		 Atopic Dermatitis (AD)
Related terms Dermatitis, Atopic
Enrollment 105 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov